Rep. Josh Gottheimer Sells Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Intra-Cellular Therapies, Inc. NASDAQ: ITCI. In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on January 24th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 1/31/2025.
• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Mastercard NYSE: MA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of 3M NYSE: MMM on 1/30/2025.

Intra-Cellular Therapies Stock Down 0.2 %

Intra-Cellular Therapies stock traded down $0.24 during trading hours on Friday, hitting $127.82. The stock had a trading volume of 1,382,004 shares, compared to its average volume of 5,987,666. Intra-Cellular Therapies, Inc. has a fifty-two week low of $62.78 and a fifty-two week high of $128.19. The company has a 50-day moving average of $105.80 and a two-hundred day moving average of $87.97. The company has a market cap of $13.59 billion, a PE ratio of -146.92 and a beta of 0.72.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. True Wealth Design LLC bought a new position in Intra-Cellular Therapies in the 3rd quarter valued at $32,000. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares during the last quarter. Capital Performance Advisors LLP bought a new position in Intra-Cellular Therapies in the 3rd quarter valued at $74,000. Venturi Wealth Management LLC bought a new position in Intra-Cellular Therapies in the 4th quarter valued at $96,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies in the 3rd quarter valued at $97,000. 92.33% of the stock is currently owned by institutional investors.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Saturday, February 8th. They issued a "hold" rating for the company. JPMorgan Chase & Co. increased their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Needham & Company LLC reissued a "hold" rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $103.62.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.